(HealthDay)—The age-adjusted U.S. cancer death rate decreased 25 percent from 1991 to 2014, which translates into 2.1 million fewer cancer deaths, according to an annual progress report published by the American Association ...
Sep 14, 2017
0
1
New immune therapies are considered a promising lead for treating recurring acute myeloid leukemia (AML). Antibodies are able to eliminate even those cancer cells that cannot be removed via regular therapies. Scientists from ...
Sep 12, 2017
0
1
Drugs developed to treat heart and blood vessel problems could be used in combination with chemotherapy to treat an aggressive form of adult leukemia, new research led by the Francis Crick Institute reveals.
Aug 31, 2017
0
91
(HealthDay)—The combination chemotherapy drug Vyxeos (daunorubicin and cytarabine) has been approved by the U.S. Food and Drug Administration as the first treatment for certain high-risk types of acute myeloid leukemia ...
Aug 3, 2017
0
2
Researchers at St. Jude Children's Research Hospital have discovered that survival of a particularly aggressive form of acute myeloid leukemia (AML) depends on production of a small molecule called heme that is a kind of ...
Aug 3, 2017
0
0
(HealthDay)—Idhifa (enasidenib) has been approved by the U.S. Food and Drug Administration to treat adults with a specific genetic mutation that leads to relapsed or refractory acute myeloid leukemia (AML).
Aug 1, 2017
0
0
Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.
Jun 28, 2017
0
636
(HealthDay)—For patients with acute myeloid leukemia (AML) and a FLT3 mutation, midostaurin plus chemotherapy is associated with prolonged overall and event-free survival, according to a study published online June 23 in ...
Jun 26, 2017
0
1
Researchers have developed a two-pronged approach to blood cancer treatment: 1) attacking cancer cells directly and/or 2) driving them from the nurturing bone marrow environment into the peripheral blood streams, where they ...
Jun 21, 2017
0
3
A new drug shows promise in its ability to target one of the most common and sinister mutations of acute myeloid leukemia (AML), according to researchers at the Perelman School of Medicine at the University of Pennsylvania ...
Jun 21, 2017
0
0
